Kaur et al. demonstrated that overexpression of the PP2A inhibitor protein PME-1 drives glioma cell resistance to various multikinase inhibitors through specific PP2A complexes and a decrease in histone deacetylase 4 cytoplasmic activity. The gene discussed is PTPA; the disease is central nervous system cancer.